Baseline demographics and disease characteristics (N=13)
| Characteristic | Patients, no (%) | |
| Age, median (range) in years | 64 (31–81) | |
| Sex | Female | 9 (69) |
| Male | 4 (31) | |
| ECOG | 0 | 10 (77) |
| 1 | 2 (15) | |
| 2 | 1 (8) | |
| Stage | IIIC | 1 (8) |
| IV-M1a | 3 (23) | |
| IV-M1b | 1 (8) | |
| IV-M1c | 6 (46) | |
| IV-M1d | 2 (15) | |
| BRAFV600 | Mutation | 5 (39) |
| Wild type | 8 (62) | |
| Prior lines of systemic therapy | Median (range) | 3 (2–9) |
| 1 or 2 | 4 (31) | |
| >2 | 9 (69) | |
| Type of prior treatment | Anti-PD-1 monotherapy | 13 (100) |
| Anti-CTLA-4 monotherapy | 12 (92) | |
| Anti-PD-1/-CTLA-4 combination | 1 (8) | |
| BRAF-/MEK-inhibition | 5 (39) | |
| Cytotoxic therapy | 6 (46) | |
| Injected lesion at baseline | No of myDC-injected lesions, median (range) | 2 (1–15) |
Tumor stage was determined according to the American Joint Committee on Cancer TNM 8th edition. Cytotoxic therapy included DTIC, temozolomide.
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ECOG, Eastern Cooperative Oncology Group; myDC, myeloid dendritic cells; PD-1, programmed death-1.